de Smet M D
Department of Ophthalmology, University of Amsterdam, Amsterdam.
Bull Soc Belge Ophtalmol. 2001(279):91-5.
Intraocular non Hodgkin's lymphoma has traditionally been treated with radiotherapy or systemic chemotherapeutic agents. Unfortunately, radiotherapy rarely leads to a long term remission, and can only be safely administered once. Systemic chemotherapy has limited intraocular penetration. Intravitreal administered methotrexate is highly effective at inducing remission and is well tolerated. A case report is presented of a recurrent intraocular lymphoma following radiotherapy and systemic chemotherapy which responded to a combination of intravitreal methotrexate and dexamethasone. A response was seen within three weeks of treatment initiation. Toxicity was limited to the progression of a pre-existing cataract. Review of the literature shows that intravitreal methotrexate is well tolerated, with few acute complications. However, with monotherapy, local recurrences have been observed.
眼内非霍奇金淋巴瘤传统上采用放射治疗或全身化疗药物进行治疗。不幸的是,放射治疗很少能导致长期缓解,且只能安全使用一次。全身化疗的眼内穿透性有限。玻璃体内注射甲氨蝶呤在诱导缓解方面非常有效,且耐受性良好。本文报告了一例放疗和全身化疗后复发的眼内淋巴瘤患者,该患者对玻璃体内注射甲氨蝶呤和地塞米松联合治疗有反应。治疗开始后三周内即见疗效。毒性仅限于原有白内障的进展。文献综述表明,玻璃体内注射甲氨蝶呤耐受性良好,急性并发症很少。然而,采用单一疗法时,已观察到局部复发情况。